journal article·2023-03-01

Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers

Diana Rafael, Sara Montero, Pilar Carcavilla, Fernanda Andrade, Júlia German-Cortés, Zamira V. Diaz-Riascos, Joaquin Seras-Franzoso, Monserrat Llaguno, Begoña Fernández, Alfredo Pereira, Esteban F. Duran-Lara, Simó Schwartz, Ibane Abasolo

Publisher page

Abstract

The Kirsten rat sarcoma viral oncogene (KRAS) is one of the most well-known proto-oncogenes, frequently mutated in pancreatic and colorectal cancers, among others. We hypothesized that the intracellular delivery of anti-KRAS antibodies (KRAS-Ab) with biodegradable polymeric micelles (PM) would block the overactivation of the KRAS-associated cascades and revert the effect of its mutation. To this end, PM-containing KRAS-Ab (PM-KRAS) were obtained using Pluronic F127. The feasibility of using PM for antibody encapsulation as well as the conformational change of the polymer and its intermolecular interactions with the antibodies was studied, for the first time, using in silico modeling. In vitro, encapsulation of KRAS-Ab allowed their intracellular delivery in different pancreatic and colorectal cancer cell lines. Interestingly, PM-KRAS promoted a high proliferation impairment in regular cultures of KRAS-mutated HCT116 and MIA PaCa-2 cells, whereas the effect was neglectable in non-mutated or KRAS-independent HCT-8 and PANC-1 cancer cells, respectively. Additionally, PM-KRAS induced a remarkable inhibition of the colony formation ability in low-attachment conditions in KRAS-mutated cells. In vivo, when compared with the vehicle, the intravenous administration of PM-KRAS significantly reduced tumor volume growth in HCT116 subcutaneous tumor-bearing mice. Analysis of the KRAS-mediated cascade in cell cultures and tumor samples showed that the effect of PM-KRAS was mediated by a significant reduction of the ERK phosphorylation and a decrease in expression in the stemness-related genes. Altogether, these results unprecedently demonstrate that the delivery of KRAS-Ab mediated by PM can safely and effectively reduce the tumorigenicity and the stemness properties of KRAS-dependent cells, thus bringing up new possibilities to reach undruggable intracellular targets.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Nanoparticle-Based Drug Delivery · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Delivery & Targeting, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona 08035, Spain

Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, Madrid 28029, Spain

Functional Validation & Preclinical Research (FVPR)/U20 ICTS Nanbiosis, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona 08035, Spain

Departament de Farmàcia i Tecnologia Farmacèutica i Fisicoquímica, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona (UB), Barcelona 08028, Spain

Departamento de Química Orgánica y Fisicoquímica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Metropolitan Region 8380492, Chile

Bio and NanoMaterials Lab, Drug Delivery and Controlled Release, Departamento de Microbiología, Facultad de Ciencias de la Salud, Universidad de Talca, P.O. Box 747, Talca, Maule 1141, Chile

Center for Nanomedicine, Diagnostic & Drug Development (ND3), Universidad de Talca, P.O. Box 747, Talca, Maule 1141, Chile

Servei de Bioquímica, Hospital Universitari Vall d’Hebron, Barcelona 08035, Spain

Funding

Ministerio de Ciencia e Innovaci??n · European Commission · Fundaci??n Cient??fica Asociaci??n Espa??ola Contra el C??ncer · Generalitat de Catalunya · Ministerio de Econom??a y Competitividad · Agencia Nacional de Investigaci??n y Desarrollo

References (53)

Show source-provided references
1. 10.1016/j.apsb.2019.03.00210.1016/j.apsb.2019.03.002 ↗
2. 10.1038/nrc296010.1038/nrc2960 ↗
3. 10.1038/nrd438910.1038/nrd4389 ↗
4. 10.3389/fonc.2022.79683210.3389/fonc.2022.796832 ↗
5. 10.1038/s41392-021-00780-410.1038/s41392-021-00780-4 ↗
6. 10.1016/j.sbi.2021.06.01310.1016/j.sbi.2021.06.013 ↗
7. 10.1016/j.ctrv.2020.10207010.1016/j.ctrv.2020.102070 ↗
8. 10.1158/2159-8290.CD-21-036510.1158/2159-8290.CD-21-0365 ↗
9. 10.1002/ijc.3272810.1002/ijc.32728 ↗
10. 10.1038/s41598-019-55091-010.1038/s41598-019-55091-0 ↗
11. 10.1021/acs.bioconjchem.9b0002510.1021/acs.bioconjchem.9b00025 ↗
12. 10.3390/pharmaceutics1202018510.3390/pharmaceutics12020185 ↗
13. 10.1039/C6QM00289G10.1039/C6QM00289G ↗
14. Andrade F. · 2018 · 211
15. Chowdhury P. · 2017 · 20710.1007/978-981-10-5864-6_9 ↗
16. 10.1016/j.jconrel.2015.04.0321010.1016/j.jconrel.2015.04.03210 ↗
17. 10.1158/1078-0432.CCR-18-238110.1158/1078-0432.CCR-18-2381 ↗
18. 10.1021/bi96251410.1021/bi962514 ↗
19. 10.1093/nar/28.1.23510.1093/nar/28.1.235 ↗
20. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P ↗
21. 10.1002/wcms.112110.1002/wcms.1121 ↗
22. 10.1002/jcc.2122410.1002/jcc.21224 ↗
23. Bowers, K. J.; Chow, D. E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. In 06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, 2006.10.1145/1188455.1188544 ↗
24. 10.2217/nnm-2016-004510.2217/nnm-2016-004510.2217/nnm-2016-004510.2217/nnm-2016-0045 ↗
25. 10.1080/10717544.2018.146127610.1080/10717544.2018.1461276 ↗
26. 10.1016/j.cej.2017.12.11410.1016/j.cej.2017.12.114 ↗
27. 10.1039/c9sm01644a10.1039/c9sm01644a ↗
28. 10.1016/j.actbio.2020.04.02810.1016/j.actbio.2020.04.028 ↗
29. 10.1038/300341a010.1038/300341a0 ↗
30. 10.3390/pharmaceutics1410213710.3390/pharmaceutics14102137 ↗
31. 10.1016/S0927-7757(00)00493-310.1016/S0927-7757(00)00493-3 ↗
32. 10.1097/MPA.0b013e3181c1596310.1097/MPA.0b013e3181c15963 ↗
33. 10.1038/s41467-017-00942-510.1038/s41467-017-00942-5 ↗
34. 10.3390/cancers1110161810.3390/cancers11101618 ↗
35. 10.1126/sciadv.aay217410.1126/sciadv.aay2174 ↗
36. 10.1080/2162402X.2018.142467410.1080/2162402X.2018.1424674 ↗
37. 10.1038/srep2501910.1038/srep25019 ↗
38. 10.1186/s13045-021-01150-x10.1186/s13045-021-01150-x ↗
39. 10.1016/j.jconrel.2021.01.02210.1016/j.jconrel.2021.01.022 ↗
40. 10.1038/nbt.333010.1038/nbt.3330 ↗
41. 10.1016/j.molimm.2010.02.01810.1016/j.molimm.2010.02.018 ↗
42. 10.1016/j.ijpharm.2015.03.05010.1016/j.ijpharm.2015.03.050 ↗
43. 10.1021/bc800231510.1021/bc8002315 ↗
44. 10.1021/jp063414910.1021/jp0634149 ↗
45. 10.1021/acsami.5b0048610.1021/acsami.5b00486 ↗
46. 10.1021/mp500298q10.1021/mp500298q ↗
47. 10.1016/j.cell.2011.12.03310.1016/j.cell.2011.12.033 ↗
48. 10.3390/cancers1320508110.3390/cancers13205081 ↗
49. 10.1016/j.xcrm.2020.10013110.1016/j.xcrm.2020.100131 ↗
50. 10.1038/oncsis.2013.3510.1038/oncsis.2013.35 ↗
51. 10.3390/cells901019810.3390/cells9010198 ↗
52. 10.3390/cells1003066710.3390/cells10030667 ↗
53. 10.26355/eurrev_202003_2067310.26355/eurrev_202003_20673 ↗